aiwiki.page
English
Science / Biology / cryopreservation

Cryopreservation

Cryopreservation preserves biological material at very low temperatures by limiting molecular activity while controlling damage from ice, solute concentration, and thermal stress.

35 keywords7 linked from5 not yet writtenWritten by AI
CellNitrogenThermodynamicsWaterpHOsmosisCell MembraneProteinCryopreser…

Cryopreservation is the preservation of biological material at temperatures sufficiently low to suppress the processes responsible for deterioration, while retaining the capacity for useful biological function after warming. Its subjects include individual cells, reproductive cells, embryos, tissues, microorganisms, and experimental biological constructs. Depending on the material and purpose, storage may use mechanical freezers, liquid nitrogen, or nitrogen vapor. Liquid nitrogen boils at approximately −196 °C at atmospheric pressure; many long-term repositories maintain samples below approximately −130 °C, although the relevant physical transitions depend on sample composition.

Low temperature alone does not ensure successful preservation. Cooling can produce ice, severe dehydration, concentrated salts, membrane disruption, and mechanical stress. Cryopreservation therefore combines temperature control with protective formulations, carefully managed cooling and warming, and tests of recovered function. Two major approaches are controlled freezing, which permits and manages extracellular ice formation, and vitrification, which seeks to avoid damaging crystallization by converting a solution into a glass-like state.

Cryopreservation underpins assisted reproduction, transplantation of blood-forming cells, microbial culture collections, agricultural breeding, and the conservation of biological diversity. It also allows experiments and manufacturing processes to use material collected at different times. Its effectiveness is highly dependent on biological scale: many isolated cells can be preserved routinely, whereas reliable preservation of large, structurally complex organs remains an active research problem.

Historical development and scientific foundations

Early investigations of biological survival at low temperature revealed an important distinction between exposure to cold and successful recovery after freezing. Some seeds, spores, and small organisms naturally tolerate extensive dehydration or freezing, whereas many mammalian cells are damaged by relatively modest ice formation. These differences helped establish cryobiology, the study of biological systems at low temperatures, as a field concerned with both natural cold tolerance and engineered preservation.

A decisive development occurred in 1949, when Christopher Polge, Audrey Smith, and Alan Parkes reported that glycerol could protect spermatozoa during freezing. Their work made low-temperature storage of animal semen practical and helped transform livestock breeding. Frozen semen subsequently enabled the long-distance distribution and prolonged storage of valuable breeding material. The importance of the discovery lay not simply in lowering temperature, but in showing that a chemical additive could alter the biological consequences of freezing.

During the 1950s and 1960s, improved refrigeration, cryogenic containers, and protective chemicals broadened the range of preservable cells. James Lovelock investigated freezing injury and membrane behavior, while work by Peter Mazur and others connected survival with water movement, cooling rate, and intracellular ice formation. Mazur’s two-factor framework explained why cells often survive poorly at both very slow and very rapid cooling rates: slow cooling can produce excessive solution-related injury, whereas rapid cooling can trap enough intracellular water to permit lethal crystallization. The framework remains influential, although different cell types and protocols do not always conform to a simple symmetrical response.

Reproductive milestones demonstrated that preserved cells could retain complex developmental functions. In 1972, David Whittingham, Stanley Leibo, and Peter Mazur reported live mice produced from embryos stored at very low temperatures. A human birth following transfer of a cryopreserved embryo was reported in 1983. In 1985, William Rall and Gregory Fahy demonstrated the preservation of mouse embryos by vitrification, establishing a major alternative to conventional freezing. Later improvements in sample handling and warming contributed to the widespread adoption of vitrification for human oocytes and embryos.

The field has consequently evolved from empirical searches for protective mixtures toward quantitative control of transport, phase behavior, and biological recovery. Modern investigations combine thermodynamics, cell physiology, materials science, and reproductive biology. Historical success with one specimen has never implied universal applicability: a formulation effective for sperm may fail for an oocyte, and a method suitable for isolated cells may be inappropriate for a vascularized tissue.

Ice formation, dehydration, and cellular injury

The central physical challenge is the behavior of water during cooling. Biological fluids contain salts, sugars, proteins, and other solutes, so they do not freeze as pure water does. Ice generally excludes most dissolved substances from its crystal lattice. As extracellular ice forms, the remaining liquid becomes progressively more concentrated, altering its osmotic properties, ionic strength, and sometimes its pH. Cells are therefore exposed not only to low temperature but also to a rapidly changing chemical environment.

Extracellular freezing commonly draws water out of cells through osmosis. This dehydration can reduce intracellular ice formation, but excessive shrinkage can damage membranes and cellular structures. During warming and removal of protective agents, the direction of water movement can reverse, producing swelling. Cell volume changes depend on membrane water permeability, the permeability of dissolved protective agents, temperature, and the duration of exposure. The cell membrane is consequently both a protective barrier and a major determinant of preservation success.

Cooling too rapidly can prevent sufficient water from leaving a cell before intracellular ice nucleates. Intracellular crystals can disrupt membranes and organelles, especially as they grow during subsequent warming. Conversely, prolonged exposure to concentrated extracellular solutions can produce membrane damage, chemical imbalance, and irreversible structural changes even without substantial intracellular ice. These competing processes explain why an optimal cooling rate is specific to a cell type, protective formulation, and sample geometry.

A simplified description of water movement uses a membrane hydraulic conductivity and an osmotic pressure difference. Near ideal dilute conditions, osmotic pressure can be approximated by

Π≈cRT,\Pi \approx cRT,

where cc is the effective osmolar concentration, RR is the gas constant, and TT is absolute temperature. Concentrated cryopreservation solutions are often nonideal, so practical modeling requires more detailed information about solute interactions and temperature-dependent transport. Such models help estimate dehydration and exposure times but do not replace biological validation.

Other injuries arise independently of, or in combination with, ice. Cooling changes membrane lipid organization, can destabilize proteins, and may disrupt the cytoskeleton. Different materials contract by different amounts, creating mechanical stresses in tissues and containers. Following warming, damaged mitochondria and disturbed cellular regulation can contribute to oxidative injury or delayed apoptosis. A cell that excludes a membrane-impermeant dye immediately after thawing may therefore still lack the capacity to divide, differentiate, or perform its intended function.

Cryoprotective agents and formulation design

A cryoprotective agent is a substance used to reduce injury during cooling, storage, or warming. Cryoprotectants can alter water activity, lower the amount of ice formed at a given temperature, promote glass formation, and modify membrane or protein stability. Their protective effects must be balanced against chemical toxicity and osmotic stress. A formulation is therefore defined not only by its ingredients but also by their concentrations, exposure temperatures, addition sequence, and removal procedure.

Common permeating agents include glycerol, dimethyl sulfoxide, ethylene glycol, and propylene glycol. They enter cells at rates that vary greatly among cell types and temperatures. Dimethyl sulfoxide is widely used for cultured mammalian cells and blood-forming cell products; concentrations around 5–10% by volume are common in particular validated protocols, but are not universal requirements. Glycerol has extensive applications in sperm and red-cell preservation, while ethylene glycol is frequently used in reproductive vitrification mixtures. A compound that crosses one cell membrane readily may enter another too slowly to prevent damaging volume changes.

Nonpermeating ingredients include sugars such as sucrose and trehalose, as well as selected polymers and macromolecules. Extracellular sugars can promote controlled cellular dehydration and help manage swelling during cryoprotectant removal. Some sugars can also stabilize membranes and proteins, but their access to intracellular compartments is a limiting factor in many mammalian cells. Research on delivery methods seeks to exploit intracellular protection without introducing unacceptable damage. Proteins and other macromolecules may reduce surface-related injury or alter ice behavior, although poorly defined biological supplements can introduce variability between batches.

Protective mixtures are often preferable to a single highly concentrated compound. Combining agents can distribute chemical toxicity while retaining sufficient glass-forming ability. Nevertheless, toxicity is not determined by total concentration alone. It can depend on exposure time, temperature, interactions among ingredients, and the biological state of the sample. Low-temperature loading may reduce some chemical reactions but also slows membrane transport, requiring longer equilibration. Stepwise addition and removal are used in many systems to limit abrupt changes in cell volume.

Formulation design also includes buffers, salts, nutrients, and the choice of carrier solution. Some buffer systems undergo substantial pH shifts when cooled or partially frozen. Serum-containing formulations may support recovery but complicate chemical definition and manufacturing consistency. For clinical and industrial applications, formulations are assessed for sterility, composition, residual protective chemicals, and compatibility with downstream processing. “Serum-free” and “animal-component-free” describe particular compositional properties; neither term by itself establishes that a formulation is suitable for every cell type or intended use.

Controlled freezing and vitrification

Controlled freezing manages the formation of extracellular ice while allowing cells to lose sufficient water to reduce intracellular crystallization. Samples are commonly cooled at a programmed rate after protective agents have equilibrated. For many mammalian cell suspensions, approximately 1 °C per minute is a frequently used starting point, not a general biological optimum. Sperm, embryos, blood cells, and organized tissues may require substantially different thermal histories. Some protocols use deliberate ice seeding to initiate extracellular freezing at a reproducible temperature rather than allowing unpredictable supercooling.

Ice nucleation releases latent heat, temporarily changing the sample’s temperature trajectory. The temperature measured in a freezer chamber is therefore not necessarily the temperature experienced by the biological material. Container size, fill volume, thermal contact, and the position of a temperature probe all affect interpretation. Programmable freezers can compensate for parts of the freezing process, whereas passive freezing devices use insulation and thermal mass to produce an approximate cooling profile. Both approaches require validation for the actual sample and container.

Vitrification instead aims to convert the liquid into an amorphous solid without damaging ice formation. As temperature falls, viscosity rises until molecular rearrangement becomes extremely slow. The resulting glass is not an equilibrium crystal, and its formation depends on both composition and thermal history. The glass transition occurs over a temperature range rather than at a universal fixed point. Vitrification solutions generally require either high concentrations of protective solutes, very rapid cooling, or a combination of both.

Small specimen volumes facilitate rapid heat transfer. Oocytes and embryos can be placed in very small droplets or thin films on specialized carriers, allowing much faster temperature changes than are possible in a large vial. Devices may expose the sample directly to liquid nitrogen or isolate it within a closed barrier. These designs involve trade-offs among heat transfer, handling, contamination control, and practical reproducibility. Avoidance of visible ice does not by itself demonstrate that the specimen remains biologically functional.

Neither controlled freezing nor vitrification is intrinsically superior for every application. Controlled freezing usually permits lower cryoprotectant concentrations but accepts ice formation and its associated stresses. Vitrification reduces some ice-related injuries but can increase chemical exposure, handling sensitivity, and the demands placed on warming. Intermediate strategies, including partial freezing followed by vitrification of the remaining concentrated liquid, also occur in practice. Protocol selection is therefore based on the specimen’s transport properties, structural requirements, and demonstrated post-warming function rather than on the method’s name alone.

Warming, storage, and quality control

Warming is an active part of preservation rather than simply the reversal of cooling. Small ice crystals can grow into larger crystals during warming, a process called recrystallization. A previously vitrified sample may also crystallize if it spends too long in a temperature range where molecular mobility permits nucleation and growth. The warming rate needed to avoid damaging ice can exceed the cooling rate needed to form a glass. Consequently, successful cooling cannot compensate for an inadequate warming procedure.

Rapid warming is often beneficial, but speed must be considered together with spatial uniformity. In small samples, rapid transfer of heat can limit ice growth. In larger specimens, external warming may heat the surface much faster than the center, creating thermal gradients, uneven cryoprotectant exposure, and mechanical stress. Following warming, protective agents must be removed without excessive swelling. Recovery conditions—including culture medium, oxygen availability, and the interval before assessment—can influence apparent survival and later biological performance.

Long-term storage generally aims to keep samples below temperatures at which appreciable molecular rearrangement and ice growth occur. A value near −130 °C is often used as an operational reference, but it is not a universal boundary for every formulation. Liquid-phase nitrogen storage provides very low temperatures, while vapor-phase systems can reduce some risks associated with direct immersion. Vapor systems nevertheless require attention to temperature gradients, especially near the top of a vessel. Mechanical freezers operating around −80 °C are suitable for some materials and durations but are not interchangeable with cryogenic storage for all specimens.

Storage reliability depends on engineering and documentation as much as on biology. Important elements include validated containers, secure seals, continuous temperature monitoring, liquid-level monitoring where applicable, alarm systems, emergency procedures, and accurate sample identification. Temporary warming during inventory searches or transport can matter even when a vessel never completely fails. Nitrogen also presents physical hazards: displaced oxygen can create an asphyxiation risk, while cryogenic liquids can cause cold injury and dangerous pressure buildup in unsuitable closed vessels.

Quality assessment must distinguish membrane integrity, viable cell number, and biological potency. Flow cytometry and microscopy can characterize cell populations, but functional assays are often essential. Examples include colony formation by blood-forming progenitors, sperm motility and fertilizing capacity, embryo development, or a therapeutic cell product’s specified activity. Reporting both percentage viability and total recovered viable cells prevents misleading comparisons. Long-term performance additionally depends on traceable records of collection, processing, storage excursions, and warming, rather than simply the number of years a sample has remained frozen.

Reproductive medicine and animal breeding

Reproductive cryopreservation includes sperm, oocytes, embryos, and selected reproductive tissues. Its importance comes from separating the time of collection from the time of fertilization, embryo transfer, or breeding. In livestock production, frozen semen has supported artificial insemination programs for decades, allowing genetic material to be distributed across large distances. Performance varies among species and individuals because sperm membrane composition, seminal plasma, cell geometry, and sensitivity to osmotic change differ substantially.

In human assisted reproduction, sperm cryopreservation is an established laboratory practice. Semen samples may contain a heterogeneous population, and preservation can reduce motility or the number of recoverable functional sperm. Assessment therefore considers more than whether individual cells remain visibly intact. Embryo cryopreservation allows embryos produced during an in vitro fertilization cycle to be stored for later transfer. Preservation may occur at different developmental stages, and outcomes depend on embryo characteristics, laboratory procedures, and the clinical context.

Mature oocytes pose distinctive problems because they are large cells with substantial water content and a delicate meiotic spindle. Disruption of microtubules, membranes, or chromosome organization can impair subsequent development. The adoption of vitrification markedly improved practical oocyte preservation compared with earlier slow-freezing approaches in many settings. However, post-warming survival is not equivalent to fertilization, embryo formation, implantation, or live birth. These are separate endpoints, each influenced by factors beyond the preservation procedure.

Ovarian tissue cryopreservation preserves tissue containing immature follicles rather than isolated mature eggs. Transplantation of cryopreserved ovarian tissue has restored endocrine activity and resulted in births. Tissue composition creates challenges absent from a single-cell suspension, including uneven protective-agent penetration and damage associated with loss and restoration of blood supply. In some diseases, the possible presence of malignant cells is an important limitation on transplantation. Testicular tissue preservation, particularly tissue collected before puberty, remains more experimental as a route to restoring human fertility.

Reproductive storage also raises questions of consent, ownership, duration, and permitted future use. Rules differ among jurisdictions and may distinguish reproductive cells, embryos, and tissue. Laboratory records must connect each specimen with its identity, collection details, treatment history, and authorization. For animal breeding and conservation, genetic representation is equally important: extensive use of a small number of preserved donors can distribute desirable traits while narrowing the breeding population. Preservation stores particular genetic material; it does not by itself determine how that material should be used.

Cell therapies, blood products, and biomedical research

Cryopreservation is central to the storage and distribution of hematopoietic stem cells obtained from bone marrow, peripheral blood, or umbilical cord blood. These products can restore blood formation after treatments that damage the marrow. Their clinical value requires recovery of cells capable of sustained hematopoiesis, not merely short-term membrane integrity. Processing, cooling, storage, transport, and warming are therefore treated as linked parts of a controlled manufacturing and clinical workflow.

Cryoprotectants remaining in a product can affect its administration. Dimethyl sulfoxide is effective in many cellular products but can produce adverse reactions during infusion, so clinical protocols account for its concentration, total amount, and handling. Washing can reduce residual cryoprotectant but may also cause cell loss or introduce additional processing stresses. These trade-offs are evaluated for particular products rather than resolved by a single universal procedure. Product release commonly incorporates identity, cell number, viability, and other measures relevant to intended activity.

Preservation is also important for immune-cell therapies, including some products based on T cells. Freezing can make manufacturing schedules more flexible and enable shipment between collection centers, manufacturing facilities, and treatment sites. However, a cell product that survives thawing may show altered proliferation, activation, migration, or functional activity. Comparisons between fresh and cryopreserved products must therefore examine appropriate biological endpoints and cannot assume equivalence solely from a high viability percentage.

Blood components illustrate the specificity of preservation methods. Red blood cells can be frozen using glycerol-based methods and subsequently processed to remove glycerol before transfusion. This is particularly valuable for selected rare blood types and specialized inventories. Other blood components have different requirements; preservation of plasma proteins, platelet function, and viable nucleated cells involves distinct objectives. The broad phrase “frozen blood” therefore conceals several technically different products.

In research, frozen cell banks make it possible to return repeatedly to an early, characterized stock rather than maintaining a culture through many passages. This reduces some forms of experimental drift and supports reproducibility. Cryopreservation is widely applied to tumor cells, induced pluripotent stem cells, and increasingly to organoids. Nevertheless, freezing can select among cell subpopulations or temporarily alter gene expression, stress responses, and metabolism. Authentication, contamination testing, and post-thaw characterization remain necessary. Samples frozen only to preserve DNA, RNA, or chemical biomarkers have a different objective: molecular integrity may be retained even when the cells are no longer viable.

Microbial collections, agriculture, and biodiversity conservation

Microbial culture collections preserve reference strains for taxonomy, biotechnology, medicine, and environmental research. Many bacteria and yeasts can be stored as frozen suspensions containing glycerol or another protective formulation. Survival nevertheless varies with species, growth phase, medium, and cell density. Repeated freeze–thaw cycles can reduce recovery or change the composition of mixed populations, so collections commonly divide material into separate units rather than repeatedly sampling the same frozen stock.

Cryopreservation complements, rather than replaces, other microbial preservation methods. Some organisms are well suited to freeze-drying, while others are damaged by dehydration or require a host cell. Viral stocks may be frozen to preserve infectivity, but their stability depends on viral structure and formulation. A recovered culture must retain the properties for which it was deposited. Viability alone does not establish genetic identity, absence of contamination, or stability of an industrially important trait.

Plant conservation presents a different range of materials. Many seeds tolerate drying and can be stored for long periods in conventional seed banks, often at approximately −18 °C. Such storage is valuable but is not equivalent to all forms of cryogenic preservation. Species with desiccation-sensitive seeds, plants propagated vegetatively, and genetically distinctive clones may require preservation of shoot tips, embryonic axes, pollen, or cultured tissues. Small shoot tips are particularly useful because they contain meristematic cells capable of regenerating a plant.

Plant protocols often combine pretreatment, osmotic dehydration, protective solutions, and rapid cooling. Some use concentrated plant vitrification solutions; others encapsulate tissues in a gel before dehydration and freezing. The central challenge is to remove or immobilize enough water without destroying regenerative capacity. Successful recovery is assessed through normal growth, not simply tissue staining. Genetic stability and epigenetic changes may also matter, particularly where preservation is combined with extended tissue culture.

For wildlife conservation, frozen repositories can retain sperm, embryos, cell lines, and other tissues from threatened populations. Their value depends on sampling design, donor identification, reproductive biology, and the availability of methods to use the stored material. Preserving many samples from closely related donors may capture less genetic diversity than a smaller but carefully representative collection. In birds, reptiles, fish, and mammals, reproductive anatomy and developmental biology create different technical constraints. A frozen cell collection is therefore a potential resource, not an automatic means of recovering a species. It cannot substitute for habitats, functioning populations, or the ecological relationships on which those populations depend.

Tissue complexity, organ preservation, and experimental frontiers

Large tissues and whole organs are difficult to preserve because conditions cannot be made uniform as readily as in a small cell suspension. A protective agent must reach different tissue compartments without excessive local exposure, and water must move across multiple barriers. Blood vessels offer a route for perfusion, but damaged or poorly perfused regions may receive insufficient protection. Different cell types within the same organ can also have incompatible tolerances to cooling rate, osmotic change, and chemical concentration.

Heat transfer introduces a second scale problem. A small droplet can cool and warm rapidly, whereas an organ develops substantial differences between its surface and center. Thermal diffusion time scales approximately with the square of a characteristic distance:

t∼L2α,t \sim \frac{L^2}{\alpha},

where LL is a characteristic length and α\alpha is thermal diffusivity. This relation explains why increasing specimen dimensions creates disproportionate difficulty. Nonuniform cooling can allow ice formation, while nonuniform warming can produce cracking, recrystallization, or local overheating.

Research on volumetric warming seeks to deliver energy throughout a sample rather than solely through its surface. One approach, often called nanowarming, disperses magnetic nanoparticles in a preservation solution and applies an alternating magnetic field to generate heat within the material. In 2023, researchers reported long-term vitrified storage, nanowarming, and transplantation of rat kidneys that supported life after removal of the recipients’ native kidneys. This was an important experimental demonstration, but it did not establish routine banking of human kidneys or other large clinical organs.

Other research examines ice-binding molecules, synthetic polymers that inhibit ice recrystallization, less toxic protective mixtures, and improved control of ice nucleation. Microfluidic systems can help regulate the addition and removal of protective agents, while computational models estimate transport and thermal stresses. Engineered tissues and organoids provide useful test systems, although success in a small construct does not establish preservation of a mature organ with its complete vasculature, architecture, and physiological workload.

Claims must distinguish short-term cellular survival, recovery of tissue function, successful transplantation, and sustained organism-level performance. Cryogenic fixation for structural imaging, including cryo-electron microscopy, may deliberately prioritize molecular structure rather than viability and is therefore not equivalent to reversible biological preservation. Likewise, cryonics—the preservation of legally deceased people in anticipation of possible future restoration—is distinct from established medical cryopreservation. No human has been restored to life after such preservation. For organ research, the demanding endpoints remain reproducible recovery of integrated function, acceptable injury, and reliable performance at clinically relevant scale.